Young J N, Choy I O, Silva N K, Obayashi D Y, Barkan H E
Division of Cardiothoracic Surgery, Children's Hospital, Oakland, Calif., USA.
J Thorac Cardiovasc Surg. 1997 Dec;114(6):1002-8; discussion 1008-9. doi: 10.1016/S0022-5223(97)70014-X.
The superiority of blood cardioplegia in pediatric cardiac surgery has not previously been challenged in a controlled clinical trial. The purpose of this study was to compare antegrade cold blood versus cold crystalloid cardioplegia in pediatric cardiac surgery.
One hundred thirty-eight pediatric patients (mean age 32 months; 95% CL 24.2 to 39.8 months; range 1 day to 15 years) were prospectively randomized to receive either cold blood (4:1 dilution, blood/Plegisol, potassium chloride 15 mEq/L; n = 62) or cold crystalloid (Plegisol; n = 76) cardioplegic solution during a variety of operations for congenital heart disease. Multiple doses of cold (4 degrees C) cardioplegic solution was administered antegradely in addition to topical cooling during ischemic arrest. Myocardial recovery and outcome measures were assessed by five clinical end points: (1) inotropic support, (2) echocardiographic assessment of ventricular function, (3) overall complication rate, (4) length of stay in the intensive care unit, and (5) 30-day survival. Multiple logistic regression and multivariate analysis of variance were used to investigate which of the following clinical determinants were contributory: (1) cardioplegia, (2) urgency of operation, (3) aortic crossclamp time, (4) age, and (5) cyanosis. Population data did not differ between the two cardioplegia groups (p > 0.05).
The most important clinical determinant of studied end points was the aortic crossclamp time (p < 0.05). The type of cardioplegic solution (blood vs crystalloid) was less important (p > 0.05). The only statistically significant difference between blood and crystalloid cardioplegia for the measured clinical end points was the level of intraoperative inotropic support (p < 0.05), although this did not correlate with any significant differences in measured ventricular function.
Our results suggest no clear clinical advantage of antegrade cold blood cardioplegia over crystalloid cardioplegia during hypothermic cardioplegic arrest in pediatric cardiac surgery. The aortic crossclamp time was the strongest predictor of measured outcomes.
血液停搏液在小儿心脏手术中的优越性此前尚未在对照临床试验中受到挑战。本研究的目的是比较小儿心脏手术中顺行冷血停搏液与冷晶体停搏液的效果。
138例小儿患者(平均年龄32个月;95%可信区间24.2至39.8个月;范围1天至15岁)被前瞻性随机分组,在各种先天性心脏病手术中接受冷血(4:1稀释,血液/普利吉索尔,氯化钾15 mEq/L;n = 62)或冷晶体(普利吉索尔;n = 76)停搏液。除了在缺血性停搏期间进行局部降温外,还顺行给予多剂冷(4℃)停搏液。通过五个临床终点评估心肌恢复和结果指标:(1)血管活性药物支持,(2)超声心动图评估心室功能,(3)总体并发症发生率,(4)重症监护病房住院时间,以及(5)30天生存率。使用多重逻辑回归和多变量方差分析来研究以下哪些临床决定因素起作用:(1)停搏液类型,(2)手术紧急程度,(3)主动脉阻断时间,(4)年龄,以及(5)紫绀。两组停搏液组的总体数据无差异(p > 0.05)。
所研究终点最重要的临床决定因素是主动脉阻断时间(p < 0.05)。停搏液类型(血液与晶体)的影响较小(p > 0.05)。血液停搏液和晶体停搏液在所测量的临床终点之间唯一具有统计学意义的差异是术中血管活性药物支持水平(p < 0.05),尽管这与所测量的心室功能的任何显著差异均无关联。
我们的结果表明,在小儿心脏手术低温停搏期间,顺行冷血停搏液相对于晶体停搏液没有明显的临床优势。主动脉阻断时间是所测量结果的最强预测因素。